Nantong Chanyoo

Nantong Chanyoo Pharmatech Co., Ltd. is a prominent Chinese pharmaceutical company specializing in the development and large-scale manufacturing of active pharmaceutical ingredients (APIs) and intermediates. As a core subsidiary of Changzhou Pharmaceutical Factory (under Shanghai Pharmaceutical Group), the company operates a major production base in the Rudong Coastal Economic Development Zone. Its product portfolio focuses heavily on cardiovascular and cerebrovascular health, featuring high-capacity production of drugs such as rosuvastatin, ticagrelor, and sacubitril. The facility is highly regulated, holding certifications from the US FDA, EU GMP, and Japan's PMDA, enabling it to serve global markets. In addition to manufacturing, Nantong Chanyoo maintains an active R&D pipeline with over 20 products in development, supported by collaborations with leading Chinese academic institutions.